BAIN CAPITAL INVESTORS LLC - 20 Apr 2026 Form 4 Insider Report for Kailera Therapeutics, Inc. (KLRA)

Source evidence Original filing metadata and source links for verification. 4 source fields
SEC form
4
Accepted by SEC
20 Apr 2026, 18:10:33 UTC
Prior SEC filing
16 Apr 2026
Source filing
View source filing
Reporting owner 1 detail
Reporting owner signature
See signatures included in Exhibit 99.1

Key filing fact

BAIN CAPITAL INVESTORS LLC filed Form 4 for Kailera Therapeutics, Inc. (KLRA) on 20 Apr 2026.

Key facts

  • This page summarizes BAIN CAPITAL INVESTORS LLC's Form 4 filing for Kailera Therapeutics, Inc. (KLRA).
  • 3 reported transactions and 5 derivative rows are listed below.
  • Accepted by SEC: 20 Apr 2026, 18:10.

Change

  • Previous filing in this sequence was filed on 16 Apr 2026.
  • Current net transaction value: $0.

Research use

  • This tells you what this filing adds before you inspect full transaction and derivative tables.
  • You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reporting Owners (5)

CIK 0001040508 Primary reporting owner

BAIN CAPITAL INVESTORS LLC

Relationship
10%+ Owner
Address
200 CLARENDON STREET, BOSTON
Signature
See signatures included in Exhibit 99.1
Signature date
20 Apr 2026
CIK 0002016388

Bain Capital XIV General Partner, LLC

Relationship
10%+ Owner
Address
200 CLARENDON STREET, BOSTON
Signature
See signatures included in Exhibit 99.1
Signature date
20 Apr 2026
CIK 0002016381

Bain Capital Fund XIV, L.P.

Relationship
10%+ Owner
Address
200 CLARENDON STREET, BOSTON
Signature
See signatures included in Exhibit 99.1
Signature date
20 Apr 2026
CIK 0002100155

BCPE Perseus Investor GP, LLC

Relationship
10%+ Owner
Address
200 CLARENDON STREET, BOSTON
Signature
See signatures included in Exhibit 99.1
Signature date
20 Apr 2026
CIK 0002100174

BCPE Perseus Investor, LP

Relationship
10%+ Owner
Address
200 CLARENDON STREET, BOSTON
Signature
See signatures included in Exhibit 99.1
Signature date
20 Apr 2026

Reported non-derivative transactions

Shares, units, or other non-derivative securities reported in this filing.

KLRA transaction

Common Stock

Conversion of derivative security

Transaction value
Shares
+17,857,143
Change %
Price
Shares after
17,857,143
Date
20 Apr 2026
Ownership
See footnotes
Footnotes
F1, F2, F3
KLRA transaction

Common Stock

Conversion of derivative security

Transaction value
Shares
+17,857,143
Change %
Price
Shares after
17,857,143
Date
20 Apr 2026
Ownership
See footnotes
Footnotes
F1, F2, F3
KLRA transaction

Common Stock

Conversion of derivative security

Transaction value
Shares
+17,857,143
Change %
Price
Shares after
17,857,143
Date
20 Apr 2026
Ownership
See footnotes
Footnotes
F1, F2, F3
KLRA transaction

Common Stock

Conversion of derivative security

Transaction value
Shares
+17,857,143
Change %
Price
Shares after
17,857,143
Date
20 Apr 2026
Ownership
See footnotes
Footnotes
F1, F2, F3
KLRA transaction

Common Stock

Conversion of derivative security

Transaction value
Shares
+17,857,143
Change %
Price
Shares after
17,857,143
Date
20 Apr 2026
Ownership
See footnotes
Footnotes
F1, F2, F3
KLRA transaction

Common Stock

Purchase

Transaction value
Shares
+8,398,438
Change %
+47%
Price
$16.00*
Shares after
26,255,581
Date
20 Apr 2026
Ownership
See footnotes
Footnotes
F2, F3
KLRA transaction

Common Stock

Purchase

Transaction value
Shares
+8,398,438
Change %
+47%
Price
$16.00*
Shares after
26,255,581
Date
20 Apr 2026
Ownership
See footnotes
Footnotes
F2, F3
KLRA transaction

Common Stock

Purchase

Transaction value
Shares
+8,398,438
Change %
+47%
Price
$16.00*
Shares after
26,255,581
Date
20 Apr 2026
Ownership
See footnotes
Footnotes
F2, F3
KLRA transaction

Common Stock

Purchase

Transaction value
Shares
+8,398,438
Change %
+47%
Price
$16.00*
Shares after
26,255,581
Date
20 Apr 2026
Ownership
See footnotes
Footnotes
F2, F3
KLRA transaction

Common Stock

Purchase

Transaction value
Shares
+8,398,438
Change %
+47%
Price
$16.00*
Shares after
26,255,581
Date
20 Apr 2026
Ownership
See footnotes
Footnotes
F2, F3

Reported derivative securities

Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.

KLRA transaction Derivative

Series B Preferred Stock

Conversion of derivative security

Transaction value
Shares
-17,857,143
Change %
-100%
Price
$0.000000*
Shares after
0
Date
20 Apr 2026
Ownership
See footnotes
Underlying class
Common Stock
Underlying amount
17,857,143
Exercise price
Footnotes
F1, F2, F3
KLRA transaction Derivative

Series B Preferred Stock

Conversion of derivative security

Transaction value
Shares
-17,857,143
Change %
-100%
Price
$0.000000*
Shares after
0
Date
20 Apr 2026
Ownership
See footnotes
Underlying class
Common Stock
Underlying amount
17,857,143
Exercise price
Footnotes
F1, F2, F3
KLRA transaction Derivative

Series B Preferred Stock

Conversion of derivative security

Transaction value
Shares
-17,857,143
Change %
-100%
Price
$0.000000*
Shares after
0
Date
20 Apr 2026
Ownership
See footnotes
Underlying class
Common Stock
Underlying amount
17,857,143
Exercise price
Footnotes
F1, F2, F3
KLRA transaction Derivative

Series B Preferred Stock

Conversion of derivative security

Transaction value
Shares
-17,857,143
Change %
-100%
Price
$0.000000*
Shares after
0
Date
20 Apr 2026
Ownership
See footnotes
Underlying class
Common Stock
Underlying amount
17,857,143
Exercise price
Footnotes
F1, F2, F3
KLRA transaction Derivative

Series B Preferred Stock

Conversion of derivative security

Transaction value
Shares
-17,857,143
Change %
-100%
Price
$0.000000*
Shares after
0
Date
20 Apr 2026
Ownership
See footnotes
Underlying class
Common Stock
Underlying amount
17,857,143
Exercise price
Footnotes
F1, F2, F3
* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 3 footnotes

Footnote F1

Each share of the Issuer's Series B Preferred Stock automatically converted into shares of the Issuer's Common Stock on a 1:1 basis upon the closing of the Issuer's initial public offering. These securities had no expiration date.

Footnote F2

Represents securities held directly by BCPE Perseus Investor, LP ("BCPE Perseus").

Footnote F3

Bain Capital Investors, LLC ("BCI") is the manager of Bain Capital XIV General Partner, LLC ("BCPE Fund XIV GP"), which is the general partner of Bain Capital Fund XIV, L.P. ("BCPE Fund XIV"), which is the managing member of BCPE Perseus Investor GP, LLC ("BCPE Perseus GP"), which is the general partner of BCPE Perseus. As a result, each of BCI, BCPE Fund XIV GP, BCPE Fund XIV and BCPE Perseus GP may be deemed to share voting and dispositive power with respect to the securities held by BCPE Perseus. BCI, BCPE Fund XIV GP, BCPE Fund XIV and BCPE Perseus GP each disclaims beneficial ownership of such securities except to the extent of its pecuniary interest therein.

We use cookies and similar technologies to provide certain features, enhance the user experience and, if you allow them, measure engagement and deliver advertising. Analytics and marketing storage stay off until you grant consent. By clicking on "Agree and continue", you declare your consent to the use of the selected optional cookies. Manage preferences to update or revoke optional consent for future visits. For more information, see our Privacy Policy .